Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Inclusion, Diversity, Equity, Anti-racism, & Social Justice (IDEAS)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit a Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

January 2019; 6 (1) EditorialOpen Access

Drugs, bugs, and MS

The interplay between disease-modifying therapy and gut microbiota

Ashutosh K. Mangalam
First published November 27, 2018, DOI: https://doi.org/10.1212/NXI.0000000000000524
Ashutosh K. Mangalam
From the Department of Pathology, University of Iowa Carver College of Medicine, Iowa City, IA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Drugs, bugs, and MS
The interplay between disease-modifying therapy and gut microbiota
Ashutosh K. Mangalam
Neurol Neuroimmunol Neuroinflamm Jan 2019, 6 (1) e524; DOI: 10.1212/NXI.0000000000000524

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
713

Share

  • Article
  • Info & Disclosures
Loading

MS is an inflammatory disease in which both genetic and environmental factors play roles in the predisposition to disease. A number of recent studies suggest that gut microbiota might be a potential environmental factor linked with the pathogenesis of MS. Trillions of bacteria residing in the human gut (gut microbiota) play an important role in maintaining a healthy state, and perturbation of the gut microbiota is associated with exacerbation and/or precipitation of MS. A number of recent studies have shown that patients with MS have gut dysbiosis characterized by altered levels of certain gut bacteria.1,–,5 Because MS is an inflammatory disease, it is hypothesized that gut bacteria enriched in patients with MS might possess proinflammatory properties, whereas those showing reduced relative abundance might be anti-inflammatory in nature.

Initial MS microbiome studies may be confounded because of disease-modifying therapies (DMTs). Hence, it is important to delineate the role of gut microbiota changes specific to disease from those influenced by DMTs. In this issue of Neurology®: Neuroimmunology & Neuroinflammation, Katz Sand et al.6 analyzed gut microbiota profile in patients with relapsing-remitting MS (RRMS). They conducted a cross-sectional study to determine the effect of 2 commonly used DMTs, dimethyl fumarate (DMF) and glatiramer acetate (GA), on gut microbiota composition in patients with RRMS. The authors recruited 75 treatment-naive RRMS patients, 33 patients with RRMS on DMF, and 60 patients with RRMS on GA at 2 different MS centers, 1 in New York, NY and another in San Francisco, CA. Although samples were collected from 2 different geographical locations, no community-level differences were detected, indicating that there was no significant effect on gut microbiota because of geography. DMF and GA treatment also had no effect on microbial richness (α-diversity) or bacterial community diversity (β-diversity), which suggests that DMTs had no major impact on overall gut microbiota composition. However, taxa-level analyses using linear discriminant analysis effect size (LEfSe) showed certain bacterial genera with increased or decreased relative abundance in DMT-treated RRMS patients compared with the treatment naive RRMS group. The DMF-treated group showed reduced relative abundance of the order Clostridiales and families Lachnospiraceae, Veillonellaceae, and Tissierellaceae. As certain species from the order Clostridiales had been linked with MS and neuromyelitis optica, it is suggested that DMTs might act through suppressing proinflammatory bacteria belonging to the order Clostridiales. However, the order Clostridiales also contains a number of bacteria with anti-inflammatory properties, especially bacteria with ability to induce CD4+FoxP3+ regulatory T cells (Tregs).7 Levels of Bacteroides also trended higher in the DMT-treated RRMS group, which contain bacteria such as Bacteroides fragilis with the ability to induce Tregs and suppress disease in experimental model of MS.8 Recent studies have shown that DMT treatment is associated with an increased relative abundance of Prevotella and Sutterella genera.3,9 However, the current study failed to find an increase in relative abundance of either Prevotella or Sutterella. The authors suggest that induction of Prevotella and Sutterella in other studies may be due to interferon beta (IFNβ) because patients with RRMS in those other studies were treated with IFNβ alone or IFNβ/GA. Thus, the jury is still out regarding the link between GA or DMF treatment and Prevotella and/or Sutterella.

Analysis of functional pathways using phylogenetic investigation of communities by reconstruction of unobserved states showed modulation of retinol (Vitamin A) metabolism in both DMF- and GA-treated groups. Because retinoic acid metabolism is linked with generation of Tregs by dendritic cells in the small intestine, it is possible that the beneficial effects of GA and DMF are through modulation of immune responses toward anti-inflammatory activity by inducing regulatory CD4 T cells (Tregs) in the gut. However, identification of metabolic pathways using either shotgun metagenomic sequencing or fecal metabolite measurements needs to be performed to validate the role of retinol metabolism in the beneficial effects of GA and DMF in patients with MS.

This study by Sand Katz et al.6 is an important first step in understanding the interplay between DMTs, gut microbiota, and MS microbiome. Their data suggest that certain bacteria belonging to a specific taxa, especially those belonging to the order Clostridiales, may play important roles in disease pathogenesis. However, in the absence of bacterial classification at the genera or species level, it is difficult to identify the specific bacterial species responsible for the beneficial effect of DMTs. This study used 150 bp paired-end sequencing, which might not achieve resolution comparable to the newer 250 or 300 bp paired-end reads. In addition, the microbiome field is moving away from operational taxonomic unit (OTU)–based gut microbiota profiling to amplicon sequence variants (ASVs) because ASVs can identify bacteria at the genus or even at the species level.10 Thus, future studies using longer paired-end reads and identifying bacterial species (ASVs) using the Divisive Amplicon Denoising Algorithm-2 (DADA-2) platform will be more informative. In the absence of a predisease group and/or healthy control group, it is difficult to conclude whether treatment with DMTs restored the gut microbiota toward a healthy microbiome or predisease state.

In conclusion, this finding suggests that DMTs might lead to subtle changes in the composition of gut microbiota and highlight its significance in MS. However, multicentric longitudinal studies will validate and authenticate the role of gut microbiota in MS. Further studies are also needed to determine whether gut dysbiosis precedes MS or it is a consequence of disease, treatment, or other unknown factors. The current study by Katz Sand et al. and previous 2 studies have laid the groundwork for future studies to determine the role of gut microbiome in the pathogenesis of MS.

Study funding

No targeted funding reported.

Disclosure

A. Mangalam receives research support from the NIH (R01AI137075); holds a patent on Use of Prevotella histicola for treatment of autoimmune condition (Licensed to Evelo Biosciences); and receives royalties from Mayo Clinic (paid by Evelo Biosciences). Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

Footnotes

  • Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at Neurology.org/NN.

  • Disease-modifying therapies alter gut microbial composition in MS

  • Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Miyake S,
    2. Kim S,
    3. Suda W, et al
    . Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV Clusters. PLoS One 2015;10:e0137429.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Chen J,
    2. Chia N,
    3. Kalari KR, et al
    . Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep 2016;6:28484.
    OpenUrlCrossRef
  3. 3.↵
    1. Jangi S,
    2. Gandhi R,
    3. Cox LM, et al
    . Alterations of the human gut microbiome in multiple sclerosis. Nat Commun 2016;7:12015.
    OpenUrlCrossRef
  4. 4.↵
    1. Berer K,
    2. Gerdes LA,
    3. Cekanaviciute E, et al
    . Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A 2017;114:10719–10724.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Cekanaviciute E,
    2. Yoo BB,
    3. Runia TF, et al
    . Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A 2017;114:10713–10718.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Katz Sand I,
    2. Zhu Y,
    3. Ntranos A, et al
    . Disease-modifying therapies alter gut microbial composition in multiple sclerosis. Neurol Neuroimmunology Neuroinflammation 2018;6:e517. doi: 10.1212/NXI.0000000000000517.
    OpenUrl
  7. 7.↵
    1. Atarashi K,
    2. Tanoue T,
    3. Oshima K, et al
    . Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. Nature 2013;500:232–236.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Ochoa-Reparaz J,
    2. Mielcarz DW,
    3. Wang Y, et al
    . A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease. Mucosal Immunol 2010;3:487–495.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Castillo-Alvarez F,
    2. Perez-Matute P,
    3. Oteo JA,
    4. Marzo-Sola ME
    . The influence of interferon beta-1b on gut microbiota composition in patients with multiple sclerosis [in Spanish]. Neurologia Epub 2018 Jun 9.
  10. 10.↵
    1. Callahan BJ,
    2. McMurdie PJ,
    3. Holmes SP
    . Exact sequence variants should replace operational taxonomic units in marker-gene data analysis. ISME J 2017;11:2639–2643.
    OpenUrl

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Study funding
    • Disclosure
    • Footnotes
    • References
  • Info & Disclosures
Advertisement

Preferences and User Experiences of Wearable Devices in Epilepsy A Systematic Review and Mixed-Methods Synthesis

Dr. Daniel Friedman and Dr. Sharon Chiang

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • All Demyelinating disease (CNS)
  • Multiple sclerosis

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (2)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise